Medi-Ject's needle-free injector goes OTC (over the counter):
This article was originally published in Clinica
Executive Summary
The FDA has given Minneapolis-based Medi-Ject the go-ahead to sell its Medi-Jector Choice needle-free insulin injector over the counter. For the past 20 years, the product has been available on prescription. It uses pressure to form a micro-thin column of insulin which is capable of penetrating the skin and dispersing in the fatty tissue within half a second.
You may also be interested in...
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.